Motilal Oswal Maintains Neutral Rating on Torrent Pharma, Sets Rs 4,970 Target

Motilal Oswal said Torrent Pharma delivered slightly better-than-expected quarterly revenue and EBITDA, up 3% and 5% against estimates, respectively. Earnings were largely in line with estimates due to a higher-than-expected tax rate.